Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

NCT00300807 is registered in ClinicalTrials.gov with XTL Biopharmaceuticals as lead sponsor.

NCT NCT00300807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00300807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection
Lead sponsor
XTL Biopharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2005
Completion date
April 30, 2007
Enrollment
36
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c